News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
68,601 Results
Type
Article (2551)
Company Profile (13)
Press Release (66037)
Multimedia
Podcasts (7)
Webinars (1)
Section
Business (26868)
Career Advice (40)
Deals (3854)
Drug Delivery (6)
Drug Development (9106)
Employer Resources (11)
FDA (1289)
Job Trends (1599)
News (37664)
Policy (2318)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (1)
Academia (184)
Accelerated approval (11)
ADA (4)
Adcomms (2)
Allergies (29)
Alliances (3668)
ALS (25)
Alzheimer's disease (234)
Antibody-drug conjugate (ADC) (91)
Approvals (1497)
Artificial intelligence (45)
ASCO (45)
Autoimmune disease (44)
Automation (5)
Bankruptcy (12)
Belgium (4)
Best Places to Work (1472)
BIO (3)
Biologics (5)
BIOSECURE Act (2)
Biosimilars (30)
BioSpace Insights (6)
Biotechnology (6)
Bispecific (7)
Bladder cancer (35)
Brain cancer (10)
Breast cancer (136)
Cancer (1025)
Cardiovascular disease (67)
Career advice (40)
Career pathing (3)
CAR-T (38)
CDC (2)
CDMO (14)
Celiac Disease (3)
Cell therapy (108)
Cervical cancer (9)
Clinical research (9108)
Collaboration (236)
Commercialization (4)
Compensation (90)
Complete response letters (5)
COVID-19 (201)
CRISPR (9)
C-suite (118)
Cystic fibrosis (31)
Data (1626)
Denatured (2)
Depression (18)
Dermatology (28)
Diabetes (78)
Diagnostics (760)
Digital health (9)
Diversity (2)
Diversity, equity & inclusion (5)
Drug discovery (46)
Drug pricing (9)
Drug shortages (1)
Duchenne muscular dystrophy (68)
Earnings (20758)
Editorial (4)
Employer branding (3)
Employer resources (12)
ESMO (72)
Events (7585)
Executive appointments (76)
Eye disease (4)
FDA (1993)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (3)
Funding (218)
Gene editing (22)
Generative AI (2)
Gene therapy (75)
GLP-1 (139)
Government (250)
Guidances (200)
Healthcare (1708)
Hematology (26)
HIV (21)
Huntington's disease (11)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (28)
Immunology and inflammation (28)
Immuno-oncology (14)
Indications (61)
Infectious disease (252)
Inflammatory bowel disease (45)
Inflation Reduction Act (1)
Influenza (16)
Intellectual property (27)
Interviews (4)
IPO (2607)
IRA (3)
Job creations (196)
Job search strategy (35)
JPM (3)
Kidney cancer (5)
Kidney disease (25)
Labor market (16)
Layoffs (44)
Legal (298)
Licensing (8)
Liver cancer (17)
Longevity (2)
Lung cancer (154)
Lung diease (2)
Lymphoma (110)
Management (2)
Manufacturing (129)
Marketing (3)
MASH (42)
Medical device (1328)
Medtech (1347)
Mergers & acquisitions (1382)
Metabolic disorders (206)
mRNA (22)
Multiple sclerosis (67)
Multispecific (1)
NASH (2)
Netherlands (5)
Neurodegenerative disease (49)
Neuropsychiatric disorders (14)
Neuroscience (481)
NextGen: Class of 2026 (399)
Non-profit (192)
Now hiring (1)
Obesity (88)
Opinion (8)
Ovarian cancer (44)
Pain (36)
Pancreatic cancer (38)
Parkinson's disease (44)
Partnered (2)
Patents (44)
Patient advocacy (1)
Patient recruitment (79)
Patient selection (8)
Peanut (13)
People (3013)
Peptides (5)
Pharmaceutical (4)
Pharmacy benefit managers (2)
Phase 1 (2237)
Phase 2 (3842)
Phase 3 (3661)
Pipeline (2687)
Policy (12)
Postmarket research (325)
Preclinical (658)
Press Release (1)
Prostate cancer (46)
Psychedelics (2)
Radiopharmaceuticals (44)
Rare diseases (169)
Real estate (387)
Recruiting (5)
Regenerative medicine (1)
Regulatory (2543)
Reports (22)
Research institute (171)
Resumes & cover letters (3)
Rett syndrome (5)
RNA editing (4)
RSV (22)
Schizophrenia (40)
Series A (34)
Series B (22)
Sickle cell disease (20)
Special edition (3)
Spinal muscular atrophy (20)
Startups (224)
Stomach cancer (4)
Substance use disorders (4)
Supply chain (6)
Tariffs (3)
The Weekly (5)
Vaccines (115)
Venture capital (14)
Weight loss (50)
Wet AMD (1)
Women's health (16)
Worklife (2)
Date
Today (20)
Last 7 days (103)
Last 30 days (344)
Last 365 days (4355)
2026 (3431)
2025 (4016)
2024 (4603)
2023 (4918)
2022 (5470)
2021 (5602)
2020 (4872)
2019 (5155)
2018 (3660)
2017 (3652)
2016 (2679)
2015 (3459)
2014 (2405)
2013 (1774)
2012 (2051)
2011 (2040)
2010 (1642)
Location
Africa (47)
Alabama (8)
Arizona (25)
Asia (3674)
Australia (563)
California (1635)
Canada (410)
China (236)
Colorado (76)
Connecticut (67)
Delaware (86)
Europe (26413)
Florida (187)
Georgia (65)
Hawaii (1)
Idaho (1)
Illinois (141)
India (20)
Indiana (128)
Iowa (1)
Japan (193)
Kansas (26)
Kentucky (4)
Louisiana (9)
Maine (18)
Maryland (226)
Massachusetts (1334)
Michigan (44)
Minnesota (96)
Missouri (15)
Montana (5)
Nebraska (1)
Nevada (16)
New Hampshire (8)
New Jersey (652)
New Mexico (1)
New York (539)
North Carolina (227)
Northern California (910)
Ohio (66)
Oklahoma (1)
Pennsylvania (363)
Puerto Rico (3)
Rhode Island (2)
South America (81)
South Carolina (3)
Southern California (631)
Tennessee (21)
Texas (238)
United States (6360)
Utah (46)
Virginia (27)
Washington D.C. (3)
Washington State (128)
Wisconsin (13)
Wyoming (1)
68,601 Results for "44".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioCardia Announces $4.4 Million Financing
June 8, 2026
·
2 min read
Press Releases
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
October 14, 2026
·
7 min read
Press Releases
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
May 7, 2026
·
15 min read
Press Releases
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
June 30, 2026
·
2 min read
Press Releases
Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity
August 5, 2026
·
16 min read
Press Releases
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
May 7, 2026
·
1 min read
Press Releases
Alkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society of Retina Specialists (ASRS) 44th Annual Meeting July 15 - 18
July 9, 2026
·
3 min read
Press Releases
Health Canada Approves Cysklar® (Cysteamine Ophthalmic Solution) 0.44% for Treatment of Corneal Crystals in People with Cystinosis
April 15, 2026
·
1 min read
Press Releases
Biokin to Present at J.P. Morgan’s 44th Annual Healthcare Conference
January 14, 2026
·
1 min read
Press Releases
Rapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform
BioTrack Capital and Yonjin Capital join Series A round alongside other investors including 3E Bioventures Capital, Proxima Ventures Ltd., and Lapam Capital Upsized and over-subscribed Series A total funding of $44 million secured Rapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging disease targets
September 4, 2025
·
1 min read
1 of 6,861
Next
